MyeloMATCH MSRP (Acute Myeloid Leukemia & Myelodysplastic Syndrome)

MyeloMATCH MSRP (Acute Myeloid Leukemia & Myelodysplastic Syndrome)

Es posible que algunos contenidos no estén disponibles en español.

Purpose of this Study

We are doing this study to see if blood and bone marrow samples can be tested in a timely manner that allows for the detection of certain markers that could guide cancer treatment.

Who Can Participate?

Eligibility

Adults ages 18+ who:
  • Are suspected to have previously untreated AML or MDS (paarticipants with AML cannot have a history of previously treated myeloproliferative neoplasms)
  • Have not received prior anti-cancer therapy for AML or MDS (previous erythroid stimulating agent is not considered prior therapy for the purposes of eligibility)
For more information about this study, please contact the study team at marty.c.cauley@duke.edu.

Age Range

18-110

Sex/Genders

Male (cisgender)
Female (cisgender)
Looking for Healthy Participants
No

What is Involved?

Description

If you choose to join this study, you will have blood draws and bone marrow samples taken for testing.

Locations

Duke University Hospital

Visit Timing

Weekdays

Compensation

No

Spanish Materials Available

Yes

Study Details

Full Title

MYELOMATCH, Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MyeloMATCH Clinical Trials

Principal Investigator

Harry
Erba

Protocol Number

PRO00116097

NCT ID

NCT05564390

Enrollment Status

Open to Enrollment